Cargando…

Assessing the economic burden of Alzheimer’s disease patients first diagnosed by specialists

BACKGROUND: It is not known if there is a differential impact on Alzheimer’s disease (AD) diagnosis and outcomes if/when patients are diagnosed with cognitive decline by specialists versus non-specialists. This study examined the cost trajectories of Medicare beneficiaries initially diagnosed by spe...

Descripción completa

Detalles Bibliográficos
Autores principales: Kirson, Noam Y., Desai, Urvi, Ristovska, Ljubica, Cummings, Alice Kate G., Birnbaum, Howard G., Ye, Wenyu, Andrews, J. Scott, Ball, Daniel, Kahle-Wrobleski, Kristin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940962/
https://www.ncbi.nlm.nih.gov/pubmed/27400711
http://dx.doi.org/10.1186/s12877-016-0303-5
_version_ 1782442227627196416
author Kirson, Noam Y.
Desai, Urvi
Ristovska, Ljubica
Cummings, Alice Kate G.
Birnbaum, Howard G.
Ye, Wenyu
Andrews, J. Scott
Ball, Daniel
Kahle-Wrobleski, Kristin
author_facet Kirson, Noam Y.
Desai, Urvi
Ristovska, Ljubica
Cummings, Alice Kate G.
Birnbaum, Howard G.
Ye, Wenyu
Andrews, J. Scott
Ball, Daniel
Kahle-Wrobleski, Kristin
author_sort Kirson, Noam Y.
collection PubMed
description BACKGROUND: It is not known if there is a differential impact on Alzheimer’s disease (AD) diagnosis and outcomes if/when patients are diagnosed with cognitive decline by specialists versus non-specialists. This study examined the cost trajectories of Medicare beneficiaries initially diagnosed by specialists compared to similar patients who received their diagnosis in primary care settings. METHODS: Patients with ≥2 claims for AD were selected from de-identified administrative claims data for US Medicare beneficiaries (5 % random sample). The earliest observed diagnosis of cognitive decline served as the index date. Patients were required to have continuous Medicare coverage for ≥12 months pre-index (baseline) and ≥12 months following the first AD diagnosis, allowing for up to 3 years from index to AD diagnosis. Time from index date to AD diagnosis was compared between those diagnosed by specialists (i.e., neurologist, psychiatrist, or geriatrician) versus non-specialists using Kaplan-Meier analyses with log-rank tests. Patient demographics, Charlson Comorbidity Index (CCI) during baseline, and annual all-cause medical costs (reimbursed by Medicare) in baseline and follow-up periods were compared across propensity-score matched cohorts. RESULTS: Patients first diagnosed with cognitive decline by specialists (n = 2593) were younger (78.8 versus 80.8 years old), more likely to be male (40 % versus 34 %), and had higher CCI scores and higher medical costs at baseline than those diagnosed by non-specialists (n = 13,961). However, patients diagnosed by specialists had a significantly shorter time to AD diagnosis, both before and after matching (mean [after matching]: 3.5 versus 4.6 months, p < 0.0001). In addition, patients diagnosed by specialists had significantly lower average total all-cause medical costs in the first 12 months after their index date, a finding that persisted after matching ($19,824 versus $25,863, p < 0.0001). Total per-patient annual medical costs were similar for the two groups starting in the second year post-index. CONCLUSIONS: Before and after matching, patients diagnosed by a specialist had a shorter time to AD diagnosis and incurred lower costs in the year following the initial cognitive decline diagnosis. Differences in costs converged during subsequent years. This suggests that seeking care from specialists may yield more timely diagnosis, appropriate care and reduced costs among those with cognitive decline.
format Online
Article
Text
id pubmed-4940962
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49409622016-07-13 Assessing the economic burden of Alzheimer’s disease patients first diagnosed by specialists Kirson, Noam Y. Desai, Urvi Ristovska, Ljubica Cummings, Alice Kate G. Birnbaum, Howard G. Ye, Wenyu Andrews, J. Scott Ball, Daniel Kahle-Wrobleski, Kristin BMC Geriatr Research Article BACKGROUND: It is not known if there is a differential impact on Alzheimer’s disease (AD) diagnosis and outcomes if/when patients are diagnosed with cognitive decline by specialists versus non-specialists. This study examined the cost trajectories of Medicare beneficiaries initially diagnosed by specialists compared to similar patients who received their diagnosis in primary care settings. METHODS: Patients with ≥2 claims for AD were selected from de-identified administrative claims data for US Medicare beneficiaries (5 % random sample). The earliest observed diagnosis of cognitive decline served as the index date. Patients were required to have continuous Medicare coverage for ≥12 months pre-index (baseline) and ≥12 months following the first AD diagnosis, allowing for up to 3 years from index to AD diagnosis. Time from index date to AD diagnosis was compared between those diagnosed by specialists (i.e., neurologist, psychiatrist, or geriatrician) versus non-specialists using Kaplan-Meier analyses with log-rank tests. Patient demographics, Charlson Comorbidity Index (CCI) during baseline, and annual all-cause medical costs (reimbursed by Medicare) in baseline and follow-up periods were compared across propensity-score matched cohorts. RESULTS: Patients first diagnosed with cognitive decline by specialists (n = 2593) were younger (78.8 versus 80.8 years old), more likely to be male (40 % versus 34 %), and had higher CCI scores and higher medical costs at baseline than those diagnosed by non-specialists (n = 13,961). However, patients diagnosed by specialists had a significantly shorter time to AD diagnosis, both before and after matching (mean [after matching]: 3.5 versus 4.6 months, p < 0.0001). In addition, patients diagnosed by specialists had significantly lower average total all-cause medical costs in the first 12 months after their index date, a finding that persisted after matching ($19,824 versus $25,863, p < 0.0001). Total per-patient annual medical costs were similar for the two groups starting in the second year post-index. CONCLUSIONS: Before and after matching, patients diagnosed by a specialist had a shorter time to AD diagnosis and incurred lower costs in the year following the initial cognitive decline diagnosis. Differences in costs converged during subsequent years. This suggests that seeking care from specialists may yield more timely diagnosis, appropriate care and reduced costs among those with cognitive decline. BioMed Central 2016-07-11 /pmc/articles/PMC4940962/ /pubmed/27400711 http://dx.doi.org/10.1186/s12877-016-0303-5 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Kirson, Noam Y.
Desai, Urvi
Ristovska, Ljubica
Cummings, Alice Kate G.
Birnbaum, Howard G.
Ye, Wenyu
Andrews, J. Scott
Ball, Daniel
Kahle-Wrobleski, Kristin
Assessing the economic burden of Alzheimer’s disease patients first diagnosed by specialists
title Assessing the economic burden of Alzheimer’s disease patients first diagnosed by specialists
title_full Assessing the economic burden of Alzheimer’s disease patients first diagnosed by specialists
title_fullStr Assessing the economic burden of Alzheimer’s disease patients first diagnosed by specialists
title_full_unstemmed Assessing the economic burden of Alzheimer’s disease patients first diagnosed by specialists
title_short Assessing the economic burden of Alzheimer’s disease patients first diagnosed by specialists
title_sort assessing the economic burden of alzheimer’s disease patients first diagnosed by specialists
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940962/
https://www.ncbi.nlm.nih.gov/pubmed/27400711
http://dx.doi.org/10.1186/s12877-016-0303-5
work_keys_str_mv AT kirsonnoamy assessingtheeconomicburdenofalzheimersdiseasepatientsfirstdiagnosedbyspecialists
AT desaiurvi assessingtheeconomicburdenofalzheimersdiseasepatientsfirstdiagnosedbyspecialists
AT ristovskaljubica assessingtheeconomicburdenofalzheimersdiseasepatientsfirstdiagnosedbyspecialists
AT cummingsalicekateg assessingtheeconomicburdenofalzheimersdiseasepatientsfirstdiagnosedbyspecialists
AT birnbaumhowardg assessingtheeconomicburdenofalzheimersdiseasepatientsfirstdiagnosedbyspecialists
AT yewenyu assessingtheeconomicburdenofalzheimersdiseasepatientsfirstdiagnosedbyspecialists
AT andrewsjscott assessingtheeconomicburdenofalzheimersdiseasepatientsfirstdiagnosedbyspecialists
AT balldaniel assessingtheeconomicburdenofalzheimersdiseasepatientsfirstdiagnosedbyspecialists
AT kahlewrobleskikristin assessingtheeconomicburdenofalzheimersdiseasepatientsfirstdiagnosedbyspecialists